EU and US could reach trade deal this weekend - Reuters
BRISBANE, CA—George Bickerstaff, a director at CareDx, Inc. (NASDAQ:CDNA), a company currently valued at $1.05 billion, recently executed a significant sale of the company’s common stock. According to a regulatory filing, Bickerstaff sold 20,000 shares on March 10, 2025, at a weighted average price of $18.3551 per share. The shares were sold in multiple transactions, with prices ranging from $18.0650 to $18.7100, totaling $367,102. InvestingPro analysis indicates the stock is currently trading below its Fair Value, despite showing high volatility in recent weeks with a -9.89% return over the past week.
Following this transaction, Bickerstaff’s direct ownership in CareDx stands at 103,027 shares. This sale was not part of an equity swap, and Bickerstaff does not hold any officer or ten percent owner roles at the company. According to InvestingPro, CareDx maintains strong financial health with a current ratio of 3.94, indicating robust liquidity. Subscribers can access 10+ additional ProTips and a comprehensive research report for deeper insights into CDNA’s investment potential.
In other recent news, CareDx, Inc. reported significant financial results for the fourth quarter and full year 2024. The company achieved a revenue of $86.6 million for the fourth quarter, marking a 32% increase year-over-year, surpassing the analysts’ expectations of $85.5 million. Earnings per share (EPS) also beat forecasts, with an actual EPS of $0.18 compared to the anticipated loss of $0.23. For the full year, CareDx’s revenue reached $333.8 million, a 19% increase from the previous year, with a net income of $52.5 million, largely attributed to a $96.3 million reversal of litigation accrual.
In terms of future guidance, CareDx has set its 2025 revenue forecast between $365 million and $375 million, indicating an approximate 17% year-over-year growth. Analysts at H.C. Wainwright have adjusted their price target for CareDx to $25.00, down from $26.00, while maintaining a Neutral rating on the stock. The analysts acknowledged the company’s consistent quarter-over-quarter growth in testing volume throughout 2024 and suggested that this momentum could extend into 2025.
CareDx ended 2024 with $261 million in cash and no debt, positioning the company for future growth initiatives, including significant product launches planned for 2025. The company also maintained a strong adjusted EBITDA gain of $27.8 million for the year, a notable improvement from a $38 million loss in 2023. These developments reflect CareDx’s robust financial health and strategic direction as it moves forward into the new fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.